APPLICATION
NDA022256
TYPE
NDA
ORIGINAL APPROVAL
2009-01-14
LATEST ACTION
2025-09-10
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription
Products
SAVELLA · ReferencePrescription
MILNACIPRAN HYDROCHLORIDE 100MG · TABLET · ORAL
SAVELLA · ReferencePrescription
MILNACIPRAN HYDROCHLORIDE 25MG · TABLET · ORAL
SAVELLA · ReferencePrescription
MILNACIPRAN HYDROCHLORIDE 50MG · TABLET · ORAL
SAVELLA · ReferencePrescription
MILNACIPRAN HYDROCHLORIDE 12.5MG · TABLET · ORAL
Approval history
2015-06-17Manufacturing (CMC) · Supplement 20 · standardAP
2015-05-21Manufacturing (CMC) · Supplement 18 · standardAP
2013-11-25Manufacturing (CMC) · Supplement 17 · standardAP
2010-06-01Manufacturing (CMC) · Supplement 5AP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.